Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
211 USD | -0.16% | -3.20% | -8.82% |
Financials (USD)
Sales 2024 * | 75.76M | Sales 2025 * | 361M | Capitalization | 4.5B |
---|---|---|---|---|---|
Net income 2024 * | -578M | Net income 2025 * | -389M | EV / Sales 2024 * | 50.2 x |
Net cash position 2024 * | 694M | Net cash position 2025 * | 292M | EV / Sales 2025 * | 11.6 x |
P/E ratio 2024 * |
-7.45
x | P/E ratio 2025 * |
-11.6
x | Employees | 376 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.94% |
Latest transcript on Madrigal Pharmaceuticals, Inc.
1 day | -0.16% | ||
1 week | -3.20% | ||
Current month | +3.41% | ||
1 month | -10.82% | ||
3 months | -3.21% | ||
6 months | +34.84% | ||
Current year | -8.82% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 11-08-31 |
William Sibold
CEO | Chief Executive Officer | - | 23-09-07 |
Rebecca Taub
FOU | Founder | 71 | 16-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 11-08-31 | |
Julian Baker
CHM | Chairman | 57 | 23-06-14 |
Ken Bate
BRD | Director/Board Member | 73 | 16-07-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.35% | 0 M€ | 0.00% | - | |
0.26% | 1,487 M€ | +7.21% | - | |
0.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 211 | -0.16% | 262,278 |
24-05-13 | 211.3 | +2.96% | 269,895 |
24-05-10 | 205.2 | -0.81% | 234,068 |
24-05-09 | 206.9 | -0.54% | 359,475 |
24-05-08 | 208 | -4.55% | 690,496 |
Delayed Quote Nasdaq, May 14, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.82% | 4.5B | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.70% | 21.25B | |
-6.03% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+5.10% | 13.94B | |
+37.57% | 12.54B |
- Stock Market
- Equities
- MDGL Stock